Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by PeriTec Biosciences Ltd..
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
PeriTec Biosciences Ltd.
Information provided by:
PeriTec Biosciences Ltd.
ClinicalTrials.gov Identifier:
NCT00542646
First received: October 10, 2007
Last updated: November 27, 2007
Last verified: November 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The occurrence of Peripheral Vascular Disease has been increasing which includes the large artery in the upper leg called Superficial Femoral Artery (SFA). The Peritoneal Lined Stent has been developed as a new method for treating narrowed area in the SFA. This research study will determine the safety and effectiveness of the Peritoneal Lined Stent in keeping th Superficial Femoral Artery open and allowing blood to flow in the leg.
| Condition | Intervention | Phase |
|---|---|---|
|
Vascular Disease, Peripheral |
Procedure: Endovascular Intervention |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System |
Resource links provided by NLM:
Further study details as provided by PeriTec Biosciences Ltd.:
Primary Outcome Measures:
- Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events [ Time Frame: 30 Days ]
Secondary Outcome Measures:
- Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization [ Time Frame: 3 Months Intervals except for Target Lesion Revascularization at 12 months ]
| Estimated Enrollment: | 45 |
| Study Start Date: | November 2006 |
| Estimated Study Completion Date: | November 2010 |
Intervention Details:
-
Procedure: Endovascular Intervention
Peritoneal Lined Stent Endovascular Intervention
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
- The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis
- Patient has a signed and dated informed consent
- Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8
- Life expectancy greater than one year
- The ability to comply with protocol follow up requirements and required testing
Angiographic lesion requirements assessed at time of procedure
- Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis
- Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
- Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention
- Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath
Exclusion Criteria:
- Untreated iliac artery in-flow limiting lesion
- Significant proximal common femoral or superficial femoral artery disease above or below target lesion
- Any previously treated superficial femoral artery lesion
- Any previous stenting or surgery in the target vessel
- Femoral or popliteal aneurysm
- Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
- Serum creatinine >2.5 mg/dl
- Any previously known coagulation disorder, including hypercoagulability
- Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00542646
Contacts
| Contact: Rajesh Khosla, MBA | 216.444.1293 | rkhosla@peritecbio.com |
| Contact: Linda Modzelewski | 216.444.5004 | lm@peritecbio.com |
Locations
| Chile | |
| Pontificia Universidad Catolica de Chile | Recruiting |
| Santiago, Chile | |
| Contact: Albrecht Kramer, MD 562.354.3233 kramer@med.puc.cl | |
Sponsors and Collaborators
PeriTec Biosciences Ltd.
Investigators
| Study Director: | Timur Sarac, MD | PeriTec Bioscience Ltd |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00542646 History of Changes |
| Other Study ID Numbers: | PB-PLS-2005-001 |
| Study First Received: | October 10, 2007 |
| Last Updated: | November 27, 2007 |
| Health Authority: | Chile: Minstry of Health |
Additional relevant MeSH terms:
|
Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Cardiovascular Diseases |
Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases |
ClinicalTrials.gov processed this record on May 23, 2013